Wiggin and Dana represented Affibody AB on the matter. Affibody AB has signed a collaboration and license agreement with Chiesi Farmaceutici S.p.A to discover, develop and commercialize innovative...
You must be a Standard 1 Year member to access this content.
Wiggin and Dana LLP represented BioInvent International AB on the license agreement with Exelixis, Inc. to develop novel antibody-based immuno-oncology therapies. The collaboration is intended to...
You must be a Standard 1 Year member to access this content.
Wiggin and Dana represented Rallybio Corporation on the acquisition. Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming...
You must be a Standard 1 Year member to access this content.
Wiggin and Dana represented Affibody AB on the deal. Affibody AB signed a partnership agreement with ACELYRIN, INC. to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A...
You must be a Standard 1 Year member to access this content.
Wiggin and Dana represented Notable Labs, Inc. on the transaction. Notable Labs, Inc.), a pioneer and developer of predictive precision medicines, has obtained worldwide rights to...
You must be a Standard 1 Year member to access this content.
